Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze, Patrick Vizeli, Felix Müller, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 3, pp. 462-471
Open Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
David E. Olson
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 563-567
Open Access | Times Cited: 237
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Anne Katrin Schlag, Jacob S. Aday, Iram Salam, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 258-272
Open Access | Times Cited: 220
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 181
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Patrick Vizeli, Laura Ley, et al.
Neuropsychopharmacology (2020) Vol. 46, Iss. 3, pp. 537-544
Open Access | Times Cited: 178
Towards an understanding of psychedelic-induced neuroplasticity
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology (2022) Vol. 48, Iss. 1, pp. 104-112
Open Access | Times Cited: 177
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Friederike Holze, Laura Ley, Felix Müller, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 6, pp. 1180-1187
Open Access | Times Cited: 147
Psychedelics reopen the social reward learning critical period
Romain Nardou, Edward J. Sawyer, Young Jun Song, et al.
Nature (2023) Vol. 618, Iss. 7966, pp. 790-798
Open Access | Times Cited: 138
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
A. Becker, Friederike Holze, Tanja Grandinetti, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 4, pp. 886-895
Open Access | Times Cited: 130
Psychedelics and Other Psychoplastogens for Treating Mental Illness
Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 113
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Must Psilocybin Always “Assist Psychotherapy”?
Guy M. Goodwin, Ekaterina Malievskaia, Gregory A. Fonzo, et al.
American Journal of Psychiatry (2023) Vol. 181, Iss. 1, pp. 20-25
Closed Access | Times Cited: 95
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
Vince Polito, Paul Liknaitzky
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104706-104706
Open Access | Times Cited: 69
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
Laura Ley, Friederike Holze, Denis Arikci, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 11, pp. 1659-1667
Open Access | Times Cited: 65
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 23
Expectancy Effects in Psychedelic Trials
Balázs Szigeti, Boris D. Heifets
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 512-521
Closed Access | Times Cited: 21
MDMA and MDMA-Assisted Therapy
Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 79-103
Closed Access | Times Cited: 3
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, et al.
European Neuropsychopharmacology (2020) Vol. 41, pp. 81-91
Open Access | Times Cited: 94
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Subacute effects of the psychedelic ayahuasca on the salience and default mode networks
Lorenzo Pasquini, Fernanda Palhano-Fontes, Dráulio Barros de Araújo
Journal of Psychopharmacology (2020) Vol. 34, Iss. 6, pp. 623-635
Open Access | Times Cited: 74
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
Classic Psychedelic Drugs: Update on Biological Mechanisms
Franz X. Vollenweider, John Smallridge
Pharmacopsychiatry (2022) Vol. 55, Iss. 03, pp. 121-138
Open Access | Times Cited: 63
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants
Friederike Holze, A. Becker, Karolina E. Kolaczynska, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 4, pp. 822-831
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top